ReviewDiagnostics (Basel, Switzerland)2015
Contrast Enhanced MRI in the Diagnosis of HCC.
Review in Diagnostics (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 41 citations in OpenAlex.
- Pharmacokinetics and safety of gadopiclenol in Japanese healthy volunteers.Japanese journal of radiology · 2025Trial
- Seroprevalence of hepatitis D among hepatitis B-infected patients attending the viral hepatitis treatment unit in Alexandria, Egypt: a prospective cross-sectional observational study.BMC infectious diseases · 2026Observational
- Prognostic Value ofCancers · 2026Article
- Single-Cell RNA-seq Reveals Deubiquitination Genes as Prognostic Markers in Hepatocellular Carcinoma.International journal of genomics · 2026Article
- Chip collection of hepatocellular carcinoma based on ONature communications · 2024Article
- Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Review
- Molecular imaging of tumour-associated pathological biomarkers with smart nanoprobe: From "Seeing" to "Measuring".Exploration (Beijing, China) · 2023Review
- Hepatocellular carcinoma: State of the art diagnostic imaging.World journal of radiology · 2023Review
- FI-CEUS: a solution to improve the diagnostic accuracy in MRI LI-RADS-indeterminate (LR-3/4) FLLs at risk for HCC.Frontiers in oncology · 2023Article
- Dictionary learning LASSO for feature selection with application to hepatocellular carcinoma grading using contrast enhanced magnetic resonance imaging.Frontiers in oncology · 2023Article
- MRI-Based Radiomic Features Help Identify Lesions and Predict Histopathological Grade of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- A novel computer-aided diagnostic system for accurate detection and grading of liver tumors.Scientific reports · 2021Article
- Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p.Cancer biomarkers : section A of Disease markers · 2021Article
- Construction of a Novel Gene-Based Model for Survival Prediction of Hepatitis B Virus Carriers With HCC Development.Frontiers in genetics · 2021Article
- GAN and dual-input two-compartment model-based training of a neural network for robust quantification of contrast uptake rate in gadoxetic acid-enhanced MRI.Medical physics · 2020Article
- Circular RNA hsa_circ_0004277 Stimulates Malignant Phenotype of Hepatocellular Carcinoma and Epithelial-Mesenchymal Transition of Peripheral Cells.Frontiers in cell and developmental biology · 2020Article
- LI-RADS 2017: An update.Journal of magnetic resonance imaging : JMRI · 2018Review
- Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: An illustrative review.World journal of radiology · 2018Review
- Liver Masses: What Physicians Need to Know About Ordering and Interpreting Liver Imaging.Current gastroenterology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the 6th most common cancer worldwide. Imaging plays a critical role in HCC screening and diagnosis. Initial screening of patients at risk for HCC is performed with ultrasound. Confirmation of HCC can then be obtained by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI), due to the relatively high specificity of both techniques. This article will focus on reviewing MRI techniques for imaging HCC, felt by many to be the exam of choice for HCC diagnosis. MRI relies heavily upon the use of gadolinium-based contrast agents and while primarily extracellular gadolinium-based contrast agents are used, there is an emerging role of hepatobiliary contrast agents in HCC imaging. The use of other non-contrast enhanced MRI techniques for assessing HCC will also be discussed and these MRI strategies will be reviewed in the context of the pathophysiology of HCC to help understand the MR imaging appearance of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.